
## Antonio Chistolini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3637355/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Secondary prophylaxis of venous thromboembolism with direct oral anticoagulants: comparison between patients with major congenital thrombophilia versus non-thrombophilic patients. Internal and Emergency Medicine, 2022, 17, 1081-1085.	2.0	2
2	Thromboembolic events following mRNA vaccines for COVID 19: a case series. Journal of Thrombosis and Thrombolysis, 2022, 53, 971-973.	2.1	4
3	Vaccine-induced immune thrombotic thrombocytopenia: a possible pathogenic role of ChAdOx1 nCoV-19 vaccine-encoded soluble SARS-CoV-2 spike protein. Haematologica, 2022, 107, 1687-1692.	3.5	10
4	lmmune thrombocytopenia management during COVIDâ€19 pandemic: An Italian monocentric experience. EJHaem, 2022, 3, 453-456.	1.0	5
5	Thromboembolic Complications in COVID-19 Patients Hospitalized in Italian Ordinary Wards: Data from the Multicenter Observational START-COVID Register. TH Open, 2022, 06, e251-e256.	1.4	2
6	Post-filter thromboembolic prophylaxis in vena cava filter carriers. Phlebology, 2021, 36, 79-80.	1.2	0
7	The treatment of upper extremities deep vein thrombosis related to thoracic outlet syndrome with direct oral anticoagulants. Phlebology, 2021, 36, 329-330.	1.2	2
8	Outcomes of longâ€ŧerm anticoagulant treatment for the secondary prophylaxis of splanchnic venous thrombosis. European Journal of Clinical Investigation, 2021, 51, e13356.	3.4	6
9	Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going?. Journal of Thrombosis and Thrombolysis, 2021, 52, 584-589.	2.1	6
10	Malignant cerebral infarction after ChAdOx1 nCov-19 vaccination: a catastrophic variant of vaccine-induced immune thrombotic thrombocytopenia. Nature Communications, 2021, 12, 4663.	12.8	47
11	Single centre experience on Acquired Haemophilia A patients: Diagnosis, clinical management and analysis of factors predictive of response and outcome. Haemophilia, 2021, 27, e667-e674.	2.1	2
12	Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutination in COVID-19 patients: another COVID-19 paradox?. Journal of Thrombosis and Thrombolysis, 2021, 52, 105-110.	2.1	18
13	Clinical course, management, and platelet activity assessment of splanchnic VITT: A case report. Thrombosis Research, 2021, 208, 14-17.	1.7	4
14	Use of edoxaban for the treatment of venous thromboembolism in <scp>HIV</scp> â€infected patients. HIV Medicine, 2020, 21, e7.	2.2	2
15	Peripherally inserted central catheters in allogeneic hematopoietic stem cell transplant recipients. Supportive Care in Cancer, 2020, 28, 4193-4199.	2.2	20
16	Secondary prophylaxis of venous thromboembolism with direct oral anticoagulants (DOACs) in patients with major congenital thrombophilia. Thrombosis Research, 2020, 196, 539-540.	1.7	2
17	Concomitant Administration of Direct Oral Anticoagulants in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors. Clinical Drug Investigation, 2020, 40, 1177-1181.	2.2	2
18	A multicenter realâ€life study on anticoagulant treatment with direct oral anticoagulants in patients with <scp>P</scp> hâ€negative myeloproliferative neoplasms. American Journal of Hematology, 2020, 95, E329-E332.	4.1	14

ANTONIO CHISTOLINI

#	Article	IF	CITATIONS
19	Direct oral anticoagulants for the treatment of Mondor's disease not responding to low-molecular weight heparin. Phlebology, 2020, 35, 734-735.	1.2	1
20	Effect of low or high doses of lowâ€molecularâ€weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVIDâ€19. British Journal of Haematology, 2020, 190, e214-e218.	2.5	25
21	Right elbow arthropathy in a patient with severe haemophilia A. British Journal of Haematology, 2020, 190, 484-484.	2.5	0
22	Direct oral anticoagulants in patients with hematologic malignancies. Hematological Oncology, 2020, 38, 589-596.	1.7	8
23	Satisfaction, quality of life and therapy adherence assessment in real life patients transitioning from vitamin K antagonists to direct oral anticoagulants. Journal of Thrombosis and Thrombolysis, 2020, 50, 718-723.	2.1	5
24	PICC-related upper deep venous thrombosis in patients with hematological malignancies. Management of anticoagulant therapy according to the platelet count. Journal of Thrombosis and Thrombolysis, 2020, 49, 426-430.	2.1	11
25	Peripherally inserted central catheter in patients with acute myeloid leukemia: incidence and risk factors for premature removal. Leukemia and Lymphoma, 2020, 61, 2265-2267.	1.3	4
26	Acquired FXIII deficiency and AL amyloidosis: A case of a rare association. Transfusion and Apheresis Science, 2020, 59, 102903.	1.0	2
27	Role of Factor V R2 Haplotype and Common Thrombophilia Markers as Genetic Risk Factors for Ischemic Stroke. Journal of Stroke Medicine, 2020, 3, 144-150.	0.3	0
28	Hemorrhagic Complications in Patients Treated With Azacitidine and Direct Oral Anticoagulants. American Journal of Therapeutics, 2020, Publish Ahead of Print, e503-e504.	0.9	2
29	Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma. British Journal of Haematology, 2019, 186, e217-e219.	2.5	1
30	DIRECT ORAL ANTICOAGULANTS IN PATIENTS AFFECTED BY MAJOR CONGENITAL THROMBOPHILIA. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019044.	1.3	16
31	The role of an accurate diagnosis of inherited thrombocytopenia as the basis for an effective treatment. A case of <i>MYH9</i> syndrome treated with a TPOâ€RA. Haemophilia, 2019, 25, e288-e290.	2.1	2
32	Antithrombin concentrate during pregnancy in congenital antithrombin deficiency. Blood Coagulation and Fibrinolysis, 2019, 30, 304-307.	1.0	1
33	Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus. Blood Transfusion, 2019, 17, 171-180.	0.4	32
34	AB0447â€Anti-Phospholipid Positivity in Healthy Subjects: Evaluation of Risk for Thrombotic Event after A 5 Years Follow-Up. Annals of the Rheumatic Diseases, 2016, 75, 1059.3-1059.	0.9	0
35	Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC). Supportive Care in Cancer, 2015, 23, 3289-3295.	2.2	39
36	EARLY AND LATE COMPLICATIONS RELATED TO CENTRAL VENOUS CATHETERS IN HAEMATOLOGICAL MALIGNANCIES: A RETROSPECTIVE ANALYSIS OF 1102 PATIENTS. Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014011.	1.3	10

#	Article	IF	CITATIONS
37	Efficacy of three different antithrombotic regimens on pregnancy outcome in pregnant women affected by recurrent pregnancy loss. Journal of Maternal-Fetal and Neonatal Medicine, 2012, 25, 1191-1194.	1.5	28
38	Sudden sensorineural hearing loss: A vascular cause? Analysis of prothrombotic risk factors in head and neck. International Journal of Audiology, 2012, 51, 800-805.	1.7	50
39	Role of Genetic and Acquired Prothrombotic Risk Factors in Genesis of Sudden Sensorineural Hearing Loss. Audiology and Neuro-Otology, 2011, 16, 185-190.	1.3	28
40	Endoscopic Evaluation of the Upper Gastrointestinal Tract is Worthwhile in Premenopausal Women with Iron-Deficiency Anaemia Irrespective of Menstrual Flow. Scandinavian Journal of Gastroenterology, 2003, 38, 239-245.	1.5	37